Further Negotiations with the Executive Office

(1) Nothing in 958 CMR 12.00 shall preclude a Referred Manufacturer from engaging in further negotiations with the Executive Office pursuant to M.G.L. c. 118E, § 12A(b) during the Commission's review of a Referred Manufacturer's Drug under 958 CMR 12.00 nor preclude the Executive Office from entering into a Supplemental Rebate agreement at a later date. (2) The Commission may close review of a Drug, with notice to the Referred Manufacturer, upon receiving a written request from the Executive Office to withdraw its referral under M.G.L. c. 118E, § 12A(g).